Gultekin SE, et al. - Herein, the authors undertook an analysis of ameloblastomas in terms of its genomic alterations, clinical presentation, and histological features. Findings disclosed that ameloblastomas harboring single BRAF mutations served as remarkable candidates for neo-adjuvant therapies with combined BRAF/MEK inhibitors. In addition, the risk of recurrence could be stratified according to the mutational spectrum.